Drugs Health Pharma

GSK’s Nucala Phase III trial shows promise in treating chronic lung disease

September 6, 2024: UK pharmaceutical giant GSK (GSK.L) announced that its asthma medicine, Nucala (mepolizumab), has shown positive results in a late-stage clinical.

Read More
X